Tanja Obradovic: Tempest Therapeutics just announced very good results from ongoing global clinical study with Amezalpat

Tanja Obradovic shared on LinkedIn: .

“Are we to expect completely new mechanism of action compound added to the standard of care in the 1st line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC)?

Tempest Therapeutics just announced very good results from ongoing global randomized Phase 1b/2 clinical study (NCT04524871) in which Amezalpat, a Peroxisome Proliferator-Activated Receptor alpha (PPARα) antagonist, delivered a six-month improvement in median overall survival (OS) advantage when combined with standard Atezolizumab and Bevacizumab in a comparison to Atezolizumab and Bevacizumab alone in the first-line treatment of patients with unresectable or metastatic HCC of 21 months vs. 15 months. Besides impressive efficacy across HCC patient subpopulations (including PDL-1 positive and negative population), safety profile of the triplet seems encouraging with no significant additional safety signals observable as added from Amezalpat or Amelzapat disrupting dosing of standard of care. This early data obtained in 70 patient trial is great news for HCC patients if pivotal trial ultimately supports these findings.”

Read further.
Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.